BACKGROUND:With steadily rising survival rates, the cause-of-death landscape for breast cancer patients is evolving. This study. AIMS:to delineate mortality patterns and demographic disparities to inform long-term survivorship strategies. METHODS:We performed a retrospective analysis of 839,698 breast cancer patients from U.S. population-based registries (2000-2021). Standardized Mortality Ratios (SMRs) and Incidence Rate Ratios (IRRs) were calculated to assess the risk of non-cancer deaths across age and racial/ethnic groups. RESULTS:By 10 years of follow-up, 48.6% of all deaths were attributed to non-cancer causes. Significant disparities emerged: Black patients (aged 0-54) exhibited the highest all-cause mortality risk (IRR: 1.70; 95% CI: 1.66-1.74), whereas Asian/Pacific Islanders (aged 65-74) showed the lowest (IRR: 0.67; 95% CI: 0.65-0.69). Notably, patients faced drastically elevated risks for external causes, including suicide (SMR: 17.4; 95% CI: 16.1-18.8) and homicide (SMR: 10.1; 95% CI: 8.37-12.13), alongside cardiovascular/non-cancer diseases. CONCLUSION:Mortality in breast cancer survivors is progressively shifting from malignancy to non-cancer causes, with distinct racial and age-dependent patterns. These findings necessitate a paradigm shift toward personalized, risk-stratified survivorship care that integrates cardiovascular monitoring and psychosocial interventions.

Background: Human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (BC) exhibits significant heterogeneity, complicating personalized treatment decisions after breast-conserving surgery (BCS). Robust tools integrating baseline risk, treatment response, and sociodemographic factors are needed to optimize survival while minimizing unnecessary toxicity. This study aimed to create a clinical decision-support tool that leverages these multifaceted factors to optimize survival outcomes and minimize treatment toxicity for these patients. Methods: Utilizing population-level data from the Surveillance, Epidemiology, and End Results (SEER) program (cases from 2010 to 2016; n=8,384), we constructed and validated prognostic nomograms for overall survival (OS) and cancer-specific survival (CSS) in a cohort of HER2-negative, T1-3N0-1 BC patients who underwent BCS followed by radiotherapy. Key prognostic variables were identified through multivariable Cox proportional hazards regression. The performance of the nomograms was rigorously assessed using the concordance index (C-index), time-dependent receiver operating characteristic (ROC) analysis, calibration curves, and decision curve analysis (DCA). Finally, risk stratification was performed by applying optimal cut-off points determined via X-tile software. Results: Key independent predictors included tumor grade, tumor (T) stage, estrogen receptor (ER)/progesterone receptor (PR) status, marital status, and single primary tumor status. Nomograms significantly outperformed American Joint Committee on Cancer (AJCC) 7th staging (OS C-index: 0.69 vs. 0.63; CSS C-index: 0.74 vs. 0.63). Patients were stratified into low- (33%), middle-, and high-risk (27%) groups. Chemotherapy provided no OS/CSS benefit in low-risk patients but substantially improved outcomes in high-risk patients (P<0.001). Achieving a complete response (CR) following neoadjuvant chemotherapy (NAC) was associated with superior survival outcomes, particularly among high-risk patients, whereas a non-complete response (NCR) was linked to worse survival. Conclusions: We developed the first validated nomograms integrating tumor biology, treatment response, and social factors to optimize HER2-negative BC management. Identifying 'single primary tumor' status as a novel prognostic indicator point to novel tumorigenesis mechanisms. Critically, our findings enable actionable strategies: low-risk patients (33%) may be candidates for avoiding chemotherapy toxicity, while high-risk patients (27%) are potential candidates for more intensive treatment strategies. Patients who fail to achieve a CR should be considered for enrollment in adjuvant trials with novel agents. Adding prospective biomarkers will further refine these precision approaches.

ObjectiveTo compare long-term survival in early-stage breast cancer patients treated with different radiation therapy modalities.MethodsData was retrospectively derived from SEER database. We compared overall survival (OS), breast cancer specific survival (BCSS) and second primary malignancies (SPM) in early-stage breast cancer patients treated with postoperative radiotherapy (PORT) versus those treated neoadjuvant radiotherapy (NART) and intraoperative radiotherapy (IORT) after propensity score matching by 1:1.ResultsA total of 457,166 patients were included in this study. After matching, the 20-year OS of 1441 patients in NART cohort was lower than that in PORT cohort (p < 0.01), particularly in hormone receptor positive patients (p < 0.01). NART were dependent prognostic factors for 20-year OS [Hazard Ratio (HR):1.21, 95%CI: 1.06-1.38, p < 0.01). No significant difference in BCSS was observed between NART and PORT treatments. Additionally, patients undergoing NART had a lower risk of all SPM (p = 0.01) and second solid cancers (p = 0.02) but a comparable risk of second hematological malignancies (p = 0.55) than patients administered PORT. HR-positive was a risk factor for SPM. No OS, BCSS or SPM risk difference were significantly observed in the 2096 pairs of IORT and PORT groups.ConclusionCompared to PORT, NART and IORT don't offer survival advantages for early-stage breast cancer patients. Altering the sequence of radiotherapy requires careful evaluation.

BACKGROUND:Suspicious calcifications in breast cancer (BC) often limit eligibility for breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC). This study assessed the impact of ductal carcinoma in situ (DCIS) status and post-NAC imaging changes on pathological complete response (pCR), BCS feasibility, and prognosis. METHODS:We retrospectively analyzed 163 BC patients with suspicious calcifications treated with NAC (median follow-up, 38.9 months). Logistic regression identified predictors of pCR, associations between calcification changes and pCR were assessed using Cramer's V, and OS and DFS were evaluated using Kaplan-Meier analysis. RESULTS:73 patients had DCIS and 90 had non-DCIS. Calcification reduction after NAC was more frequent in non-DCIS group (56.7%; p = 0.012). pCR rates were higher in non-DCIS group than in DCIS group (73.7% vs 26.3%; p = 0.015). After adjustment, DCIS was associated with reduced pCR rates (OR: 0.26, 95% CI: 0.08-0.73). Overall BCS rate was 11%. Calcification reduction showed a weak correlation with pCR (Cramer's V = 0.321). No significant OS, DFS, or BCS differences were observed by DCIS status or calcification change within follow-up. CONCLUSION:DCIS is associated with reduced pCR after NAC. Calcification findings alone should be interpreted cautiously, and BCS feasibility should be assessed using comprehensive surgical criteria.

BACKGROUND:Angiosarcoma, a rare and highly aggressive malignancy originating from vascular endothelial cells, is characterized by its rapid progression, high invasiveness, and poor prognosis. Due to the limited understanding of its tumor microenvironment (TME) and the absence of effective treatments, further research is essential to elucidate its pathogenic mechanisms and improve therapeutic strategies. OBJECTIVE:This study aims to characterize the cellular heterogeneity and unique TME of primary breast angiosarcoma using single-cell RNA sequencing (scRNA-seq), to identify potential therapeutic targets and improve clinical outcomes. METHODS:Tumor samples were obtained from a patient with bilateral primary breast angiosarcoma and two patients with invasive breast cancer. Single-cell RNA sequencing (scRNA-seq) was conducted to capture the transcriptomic profiles of individual cells within the tumor samples. Following stringent quality control, a total of 31,771 cells were analyzed using comprehensive bioinformatics approaches. Cell populations were identified and classified into distinct cell types, and differential gene expression analysis was performed to explore key signaling pathways. Functional enrichment analysis was used to identify pathways related to tumor progression and immune evasion. Additionally, cell-cell communication networks were mapped to understand interactions within the TME, with a focus on pathways that may serve as therapeutic targets. RESULTS:The scRNA-seq analysis revealed significant differences in the distribution of perivascular cells, fibroblasts, T cells, endothelial cells, and myeloid cells in breast angiosarcoma compared to invasive breast cancer. Key pathways enriched in angiosarcoma samples included growth factor binding, platelet-derived growth factor binding, and ribosome biogenesis, with abnormal expression of several ribosomal proteins. Notably, genes such as FAT4, KDR, FN1, and KIT were highly expressed in angiosarcoma endothelial cells, correlating with poor prognosis. Cell communication analysis highlighted the CXCL12-CXCR4 axis as a crucial mediator of the TME in angiosarcoma. CONCLUSION:This study provides critical insights into the TME of primary breast angiosarcoma, highlighting potential molecular targets and pathways for therapeutic intervention. These findings may inform the development of more effective treatment strategies for this rare and challenging tumor type.

Breast angiosarcoma (BAS) is a rare, aggressive malignancy with a poor prognosis, often challenging to assess due to its unique biology. This study aimed to develop a nomogram to predict 3- and 5-year overall survival (OS) for BAS patients using key clinicopathological factors. Data from 450 BAS patients diagnosed between 2000 and 2021 were extracted from SEER database. Key variables, including age, tumor size, tumor grade, and distant metastasis status, were identified through univariate and multivariate Cox regression analyses. These factors were incorporated into a nomogram for OS prediction. The model was validated internally and externally using the concordance index (C-index), calibration curves, and decision curve analysis (DCA) to assess its predictive accuracy and clinical utility. The nomogram demonstrated good predictive accuracy, with a C-index of 0.68 in the training set and 0.72 in the test set. ROC analysis indicated strong short-term predictive power, with AUC values of 0.81 and 0.75 for 1-year survival in the training and test sets, respectively, though predictive performance declined over time. DCA showed substantial clinical benefit for 12-month predictions, which diminished over longer time frames. The model effectively distinguished high-risk BAS patients and provided individualized survival estimates, supporting its potential use in clinical decision-making. This study presents the first BAS nomogram for OS prediction, showing robust short-term accuracy. The long-term utility is limited by heterogeneity and sample size, highlighting the need for external validation to confirm generalizability and clinical applicability.

Background:Breast cancer (BC) in women of reproductive age (<45 years) is characterized by aggressive biology and elevated recurrence risk despite curative breast-conserving surgery (BCS) and radiotherapy. Current staging systems inadequately predict outcomes in this population, necessitating precision tools to guide therapy. This study aims to develop validated nomograms integrating clinicopathologic variables to improve survival prediction and therapeutic personalization for young operable BC patients. Methods:Using the Surveillance, Epidemiology, and End Results (SEER) database (2010-2016), we analyzed 9,477 women aged 20-45 years with operable BC (T1-3N0-1M0) treated with BCS and radiotherapy. Prognostic factors for overall survival (OS) and cancer-specific survival (CSS) were identified via Cox regression. Nomograms integrating clinicopathologic variables were developed (training cohort: n=6,633) and validated (test cohort: n=2,844) using C-index, time-dependent receiver operating characteristic (ROC) curves, and decision curve analysis. Chemotherapy benefits were assessed across different risk subgroups. Results:Tumor grade [poorly differentiated: hazard ratio (HR) =4.46 for OS; HR =6.01 for CSS], lymph node metastasis (N1: HR =1.96 for OS; HR =2.25 for CSS), and multiple primaries which was defined as 2nd of two or more primaries (HR =2.33 for OS) independently predicted poorer survival. Human epidermal growth factor receptor 2 (HER2) positivity (HR =0.54 for OS) and progesterone receptor (PR) positivity (HR =0.50 for CSS) were protective factors. Nomograms outperformed the American Joint Committee on Cancer (AJCC) 7th edition staging system, with C-indices of 0.77 (OS) and 0.82 (CSS) in training, and 0.75 (OS) and 0.78 (CSS) in validation. Chemotherapy worsened outcomes in low-risk patient but benefited high-risk subgroups, particularly neoadjuvant chemotherapy for patients with complete response (HR =0.41 for OS). Conclusions:This study establishes validated nomograms that improve survival prediction for young, operable BC patients, identifying high-risk subgroups likely to benefit from neoadjuvant chemotherapy. Conversely, low-risk patients may be spared unnecessary treatment. Prospective validation integrating molecular biomarkers is warranted to refine therapeutic personalization.

In situ vaccination (ISV) has emerged as a promising strategy in cancer immunotherapy, offering a targeted approach that uses the tumor microenvironment (TME) to stimulate an immune response directly at the tumor site. This method minimizes systemic exposure while maintaining therapeutic efficacy and enhancing safety. Recent advances in nanotechnology have enabled new approaches to ISV by utilizing nanomaterials with unique properties, including enhanced permeability, retention, and controlled drug release. ISV employing nanomaterials can induce immunogenic cell death and reverse the immunosuppressive and hypoxic TME, thereby converting a “cold” tumor into a “hot” tumor and facilitating a more robust immune response. This review examines the mechanisms through which nanomaterials-based ISV enhances anti-tumor immunity, summarizes clinical applications of these strategies, and evaluates its capacity to serve as a neoadjuvant therapy for eliminating micrometastases in early-stage cancer patients. Challenges associated with the clinical translation of nanomaterials-based ISV, including nanomaterial metabolism, optimization of treatment protocols, and integration with other therapies such as radiotherapy, chemotherapy, and photothermal therapy, are also discussed. Advances in nanotechnology and immunotherapy continue to expand the possible applications of ISV, potentially leading to improved outcomes across a broad range of cancer types.

Background:Despite advances in human epidermal growth factor receptor 2 (HER2)-targeted therapies, HER2-positive early-stage breast cancer (BC) exhibits substantial outcome heterogeneity after breast-conserving surgery (BCS), complicating personalized chemotherapy sequencing. Robust tools integrating clinicopathological variables and treatment response are urgently needed to optimize survival while minimizing overtreatment. This study aimed to develop and validate a novel prognostic tool for this specific patient population. Methods:Using Surveillance, Epidemiology, and End Results (SEER) data [2010-2016; HER2-positive T1-3N0-1 BC patients (n=13,875) treated with BCS and radiotherapy], we developed and validated nomograms predicting overall and cancer-specific survival (CSS). Multivariable Cox regression identified prognostic factors, with nomogram performance evaluated via concordance index (C-index), time-dependent area under the curve (AUC), calibration, and decision curve analysis (DCA). Risk stratification used X-tile-derived thresholds. Results:Key independent predictors included tumor sequence [multiple primaries: overall survival (OS) hazard ratio (HR) =2.70], T stage (T2/T3: OS HR =1.79), nodal involvement (N1: OS HR =1.51), marital status (unmarried: OS HR =1.81), and chemotherapy administration (protective OS HR =0.44). Nomograms significantly outperformed American Joint Committee on Cancer (AJCC) 7th staging (OS C-index: 0.72 vs. 0.55; CSS C-index: 0.71 vs. 0.64; both P<0.001). Patients were stratified into low-, intermediate-, and high-risk groups. Adjuvant chemotherapy demonstrated improved OS in low- and middle-risk groups compared with no chemotherapy, though it showed no significant benefit for CSS. Similarly, neoadjuvant chemotherapy (NAC) improved OS only in low- and middle-risk group patients who achieved a complete response (CR), but likewise conferred no significant CSS benefit. High-risk patients achieving NAC-induced CR showed superior CSS versus adjuvant chemotherapy, while non-CR (NCR) patients derived no survival benefit. Within the high-risk group, patients who achieved CR demonstrated significantly improved OS and CSS compared to those with NCR. Conclusions:We present the first validated nomograms integrating tumor multiplicity, sociodemographic factors, and treatment response for HER2-positive BC. "Multiple primary tumors" emerged as a novel prognostic indicator, suggesting unexplored biological aggression. Our risk stratification translates to actionable strategies: chemotherapy de-escalation may be warranted in low-risk patients, as they derive no clear CSS benefit from NAC. Conversely, patients within the high-risk category are more likely to benefit from NAC and should be prioritized for this treatment to maximize survival gains. Prospective integration of targeted therapy data will refine these precision oncology tools.

Large cohort studies examining trends in cancer-related suicide are lacking. We analyzed data from the Surveillance, Epidemiology, and End Results (SEER) database, encompassing a total of 4,870,410 patients diagnosed with cancer from 1975 to 2017 in the United States. Joinpoint regression was used to estimate the annual percent change (APC) and average annual percentage change (AAPC) of age-adjusted rates of suicide. In the past 40 years, we revealed a gradual increase in cancer-related suicide rates from 1975 to 1989, followed by a gradual decrease from 1989 to 2013, and a marked decrease from 2013 to 2017. These trends suggested the potential impact of advancements in psychosocial care for patients with cancer in contributing to the observed decrease in suicide rates.

Primary acinic cell carcinoma (PACC) of the breast is a rare oncological entity that mimics acinar cell differentiation similar to that observed in salivary glands. This distinct subtype is characterized by low-grade malignancy and has only been documented in a limited number of cases. Despite its classification frequently as TNBC, PACC of the breast typically shows a comparatively favorable prognosis. Our study aims to enrich the current understanding of PACC through a comprehensive review of cases managed at our institution, analyzing their clinical, histopathological, and therapeutic profiles including chemotherapy and radiation therapy, and patient outcomes and allows us to compile a comprehensive dataset for in-depth analysis of treatment responses and long-term survival rates, contributing to a broader understanding of the disease's natural history.

As the positive results of multiple clinical trials were released, the Programmed cell death 1 (PD-1) and Programmed cell death ligand 1 (PD-L1) inhibitors emerge as the focus of integrative breast cancer treatment. PD-1/PD-L1 inhibitors are often used as a sequential agent to be combined with other agents such as chemotherapeutic agents, targeted agents, and radiation therapy. As multiple therapies are administered simultaneously or in sequence, they are prone to a variety of adverse effects on patients while achieving efficacy. It is a challenge for clinicians to maintaining the balance between immune-related adverse effects(irAEs) and treatment efficacy. Previous literatures have paid lots of attention on the adverse effects caused by immunosuppressive agents themselves, while there is a dearth of the research on the management of adverse immune effects during the combination of immunotherapy with other treatments. In this review, we discuss the overall incidence of irAEs caused by PD-1/PD-L1 inhibitors in combination with various types of treatments in breast cancer, including chemotherapy, CTLA-4 inhibitors, targeted therapy, and radiotherapy, and systematically summarizes the clinical management to each organ-related adverse immune reaction. It is important to emphasize that in the event of irAEs such as neurological, hematologic, and cardiac toxicity, there is no alternative treatment but to terminate immunotherapy. Thus, seeking more effective strategy of irAEs' management is imminent and clinicians are urged to raise the awareness of the management of adverse immune reactions.

Compared to patients of pathological complete response (pCR), patients of residual lesion afterwards neoadjuvant chemotherapy (NAC) have worse prognosis and higher distant metastasis. Irrespective, there exists limited data on effective indicators and treatment methods for these patients. In our study, we evaluated the relationship between stanniocalcin-2 (STC2) marker and the prognosis of breast cancer patients of residual lesion after receiving NAC. The relationship between STC2 and patients’ prognosis was evaluated by transcriptome analysis. The impact of the level of STC2 on cell migration, invasion, and proliferation was evaluated at the cellular level. Immunohistochemistry was performed on 293 patients with residual disease after NAC to assess STC2 protein levels. The relationship between STC2 and survival rate was estimated using Cox regression model and Kaplan Meier analysis. The results demonstrated that high level of STC2 significantly inhibited migration, invasion, and proliferation of breast cancer cells. Compared to patients with low STC2, high STC2 were directly proportional to overall survival (OS) and disease-free survival (DFS) (OS: 86.96 vs. 84.62 months, P = 0.017 DFS: 77.33 vs. 66.95 months, P-value < 0.001). In conclusion, our research suggested that the of level STC2 may be a promising prognostic marker or therapeutic targe for breast cancer patients with residual lesion after NAC.

BackgroundTriple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer lacking hormone receptors and HER2 expression, leading to limited treatment options and poor prognosis. Mitophagy, a selective autophagy process targeting damaged mitochondria, plays a complex role in cancer progression, yet its prognostic significance in TNBC is not well understood.MethodsThis study utilized single-cell RNA sequencing data from the TCGA and GEO databases to identify mitophagy-related genes (MRGs) associated with TNBC. A prognostic model was developed using univariate Cox analysis and LASSO regression. The model was validated across multiple independent cohorts, and correlations between MRG expression, immune infiltration, and drug sensitivity were explored.ResultsNine key MRGs were identified and used to stratify TNBC patients into high-risk and low-risk groups, with the high-risk group showing significantly worse survival outcomes. The model demonstrated strong predictive accuracy across various datasets. Additionally, the study revealed a correlation between higher MRG expression levels and increased immune cell infiltration, as well as potential responsiveness to specific chemotherapeutic agents.ConclusionThe mitophagy-related prognostic model offers a novel method for predicting outcomes in TNBC patients and highlights the role of mitophagy in influencing the tumor microenvironment, with potential applications in personalized treatment strategies.

Breast cancer has become the most common cancer worldwide. Despite the major advances made in the past few decades in the treatment of breast cancer using a combination of chemotherapy, endocrine therapy, and immunotherapy, the genesis, treatment, recurrence, and metastasis of this disease continue to pose significant difficulties. New treatment approaches are therefore urgently required. Zinc is an important trace element that is involved in regulating various enzymatic, metabolic, and cellular processes in the human body. Several studies have shown that abnormal zinc homeostasis can lead to the onset and progression of various diseases, including breast cancer. This review highlights the role played by zinc transporters in pathogenesis, apoptosis, signal transduction, and potential clinical applications in breast cancer. Additionally, the translation of the clinical applications of zinc and associated molecules in breast cancer, as well as the recent developments in the zinc-related drug targets for breast cancer treatment, is discussed. These developments offer novel insights into understanding the concepts and approaches that could be used for the diagnosis and management of breast cancer.

The risk of subsequent cerebrovascular disease among cancer patients of multiple cancers in the US is not well understood. A total of 3,843,261 cancer patients diagnosed from 1975 to 2018, were included from the surveillance, epidemiology, and end results (SEER) database. Standardized mortality ratios (SMRs) and absolute excess risks (AERs) were estimated. The overall cerebrovascular disease SMR was 1.04 (95% CI, 1.03-1.04), and the AER per 10,000 person-years at risk was 0.89. When compared with the US general population, greater cerebrovascular disease risk was correlated with certain cancer sites, American Indian/Alaska Native race, Asian or Pacific Islander race, unmarried marital status, distant metastasis, younger age, and an earlier time of cancer diagnosis. Clinically, more precision and proactive strategies for cerebrovascular disease prevention are required to subgroup of cancer patients with a greater risk of cerebrovascular disease, especially within the first two months.

AGR2 is a secreted protein widely existing in breast. In precancerous lesions, primary tumors and metastatic tumors, the expression of AGR2 is increased, which has aroused our interest. This review introduces the gene and protein structure of AGR2. Its endoplasmic reticulum retention sequence, protein disulfide isomerase active site and multiple protein binding sequences endow AGR2 with diverse functions inside and outside breast cancer cells. This review also enumerates the role of AGR2 in the progress and prognosis of breast cancer, and emphasizes that AGR2 can be a promising biomarker and a target for immunotherapy of breast cancer, providing new ideas for early diagnosis and treatment of breast cancer.

Triple-negative breast cancer (TNBC), a heterogeneous tumour that lacks the expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), is often characterized by aggressiveness and tends to recur or metastasize. TNBC lacks therapeutic targets compared with other subtypes and is not sensitive to endocrine therapy or targeted therapy except chemotherapy. Therefore, identifying the prognostic characteristics and valid therapeutic targets of TNBC could facilitate early personalized treatment. Due to the rapid development of various technologies, researchers are increasingly focusing on integrating 'big data' and biological systems, which is referred to as 'omics', as a means of resolving it. Transcriptomics and proteomics analyses play an essential role in exploring prospective biomarkers and potential therapeutic targets for triple-negative breast cancers, which provides a powerful engine for TNBC's therapeutic discovery when combined with complementary information. Here, we review the recent progress of TNBC research in transcriptomics and proteomics to identify possible therapeutic goals and improve the survival of patients with triple-negative breast cancer. Also, researchers may benefit from this article to catalyse further analysis and investigation to decipher the global picture of TNBC cancer.

Chyle leakage is a rare benign complication that can occur after axillary lymph node dissection. It may delay wound healing, extend hospitalization, impair the immune system, and affect the start time of adjuvant therapy. We herein present two cases of chyle leakage following left-side modified radical mastectomy in two patients with invasive carcinoma of the left breast. In such cases, treatment should begin with conservative measures, including reducing lymph production and flow. When a conservative strategy is unsuccessful, surgery or interventional procedures are necessary. Breast surgeons should be mindful of possible chyle leakage when operating in the axilla and be familiar with its treatment.

Biological and synthetic meshes were used to cover the damaged muscle and augment the subpectoral pocket in breast reconstruction. However, few studies have directly compared the effects of biological and synthetic meshes. This study analyzed postoperative complications and assessed the patient-reported outcomes with the use of BioDesign® Surgisis and TiLOOP Bra/TiMesh® in one-stage implant-based breast reconstruction. Patients undergoing one-stage implant-based breast reconstruction were enrolled in this study. Post-mastectomy breast reconstructions were facilitated with either Surgisis mesh or TiLOOP mesh. Complications were examined and patient-reported quality-of-life outcomes were evaluated using the BREAST-Q questionnaire (ver 2.0). The multivariate linear regression models were used for data analysis. Overall, 79 of 116 patients (68%) received breast reconstruction with Surgisis mesh and 37 (32%) with TiLOOP mesh. There was no difference in complication rates between the two groups postoperatively. But patient-reported satisfaction was higher with the use of Surgisis mesh than with TiLOOP mesh (P = 0.05). This study reported no difference between the Surgisis group and the TiLOOP group in either complication rates or most patient-reported outcomes postoperatively. Yet the assessment of patient-reported satisfaction showed preference toward Surgisis mesh, a finding with a potential implication for mesh selection.